Article Information
History
- May 7, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Mammen P. Mammen Jr., MD1,#,
- Pablo Tebas, MD3,#,
- Joseph Agnes, PhD1,#,
- Mary Giffear, BS1,
- Kimberly A. Kraynyak, PhD1,
- Elliott Blackwood, MS1,
- Dinah Amante, BS1,
- Emma L. Reuschel, PhD2,
- Mansi Purwar, PhD2,
- Aaron Christensen-Quick, PhD1,
- Nieman Liu, MS1,
- Viviane M. Andrade, PhD1,
- Julie Carter, MPH1,
- Gabriella Garufi, PhD1,
- Malissa C. Diehl, PhD1,
- Albert Sylvester, MS1,
- Matthew P. Morrow, PhD1,
- Patrick Pezzoli, BS1,
- Abhijeet J. Kulkarni, MS2,
- Faraz I. Zaidi, MS2,
- Drew Frase, MS2,
- Kevin Liaw, PhD2,
- Hedieh Badie, PhD1,
- Keiko O. Simon, PhD1,
- Trevor R.F. Smith, PhD1,
- Stephanie Ramos, PhD1,
- Robert Spitz, MD4,
- Robert J. Juba, MSCEP1,
- Jessica Lee, MPH1,
- Michael Dallas, PhD1,
- Ami Shah Brown, PhD1,
- Jacqueline E. Shea, PhD1,
- J. Joseph Kim, PhD1,
- David B. Weiner, PhD2,
- Kate E. Broderick, PhD1,
- Jean D. Boyer, PhD1 and
- Laurent M. Humeau, PhD1,$
- 1Inovio Pharmaceuticals, Plymouth Meeting, PA, 19462, USA
- 2Vaccine and Immunotherapy Center, Wistar Institute, Philadelphia, PA, 19104, USA
- 3Hospital of the University of Pennsylvania, Philadelphia, PA, USA
- 4ICON GPHS, Hinckley, OH 44233, USA
- ↵$Corresponding author – Inovio Pharmaceuticals, 660W Germantown Pike, Suite #110, Plymouth Meeting, PA, 19462, USA. laurent.humeau{at}inovio.com
↵# Drs. Mammen, Tebas and Agnes equally contributed to this work
Posted May 07, 2021.
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
